Beraprost


Also found in: Wikipedia.

Beraprost

An oral prostacyclin PGI2 analogue with vasodilator, antiplatelet, and cytoprotective effects, used to manage pulmonary arterial hypertension. Beraprost improves exercise capacity and symptoms in NYHA-functional class-II and -III patients with PAH and, in particular, in those with primary pulmonary hypertension.

Adverse effects
Headache, facial flushing, vasodilation.

Beraprost®

Epoprostenol A formulation of prostacyclin in trials for pulmonary vascular disease 2º to treatment with diet drugs
References in periodicals archive ?
He had been taking clopidogrel, aspirin, and beraprost following infrarenal abdominal aortic aneurysm repair since 2013.
2] itself and several IP agonists such as beraprost and iloprost are now used to treat pulmonary arterial hypertension, chronic arterial occlusion, and other diseases in which the blood vessels are constricted and blood cannot flow to the tissues.
Algunos de los prostanoides disponibles en la actualidad son: epoprostenol (intravenoso), treprostinil (subcutaneo), beraprost (oral) e iloprost (inhalado) (Castro et al 2003).
The same group also found that the prostaglandin I2 analogue beraprost sodium could also reverse the effects of ioversol on caspases and Bax/Bcl-2 [56] by phosphorylation of the cAMP-responsive element binding protein (CREB) via a PKA-dependent mechanism.
For example, Beraprost, an oral prostaglandin is proving helpful in extending exercise limits (Harvey, S.
They exceed the improvements reported for other conventional PAD drug therapies including pentoxifylline, cilostazol, dipyridamole, ticlopidine, beraprost, iloprost, naftidrofuryl, and statins, Dr.
The author included 13 studies with different analogues of PGE11 (Iloprost, Beraprost and AS-013).
Key words: Pulmonary arterial hypertension, prostacylin, epoprostenol, treprostonil, iloprost, beraprost
TSE: 4503) today announced that Toray has obtained marketing approval for its oral PGI2 derivative prolonged release, Careload(R) LA Tablets 60mu/g (generic name: beraprost sodium), to be indicated for pulmonary arterial hypertension (PAH) on October 19,2007.
Beraprost is used in Japan, but has not yet been approved in the United States.
The eagerly anticipated new agents are ioprost, an inhaled prosracyclin analogue that can be given by nebulizer several times per day; treprostinil (Remodulin), a subcutaneously administered prostacycin analogue; and Beraprost, an orally active prosracyclin analogue.